Inotek Makes Board Appointment
This article was originally published in Scrip
Lexington, Massachusetts-based Inotek Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, has named Carsten Boess to its board of directors and board audit committee. Boess is currently chief business officer at Kiniksa Pharmaceuticals, a privately held biotechnology company. Previously he was senior vice president and chief financial officer at Synageva Biopharma Corporation from 2011 until the company's acquisition by Alexion Pharmaceuticals in 2015.